<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151746</url>
  </required_header>
  <id_info>
    <org_study_id>STU00205047</org_study_id>
    <nct_id>NCT03151746</nct_id>
  </id_info>
  <brief_title>Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion</brief_title>
  <official_title>Effect of Preoperative Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion: a Double Blind, Randomized, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's objective is to determine the efficacy of preoperative gabapentin in relieving&#xD;
      postoperative pain, reducing opioid use and improving quality of recovery in subjects&#xD;
      undergoing urologic surgery.&#xD;
&#xD;
      Investigators hypothesize that subjects receiving gabapentin will have lower pain scores,&#xD;
      less opioid consumption and better quality of recovery as compared to subjects who are given&#xD;
      a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately one hour prior to induction of anesthesia in preoperative holding area all&#xD;
      enrolled subjects will receive PO Acetaminophen 650 mg, the Gabapentin group will receive PO&#xD;
      Gabapentin 1200 mg, while the Control group will receive PO Placebo, with a small amount of&#xD;
      water.&#xD;
&#xD;
      Upon arrival in the operating room, standard ASA monitors will be applied. Intraoperative,&#xD;
      patients will receive a standardized anesthetic care. This care consists of induction with IV&#xD;
      propofol 2mg/kg, IV fentanyl 2 mcg/kg (adjusted body weight), and IV rocuronium 0.6 mg/kg for&#xD;
      tracheal intubation or IV succinylcholine 1mg/kg if rapid sequence induction is needed.&#xD;
&#xD;
      For maintenance of general anesthesia, investigators will use Sevoflurane, with the goal to&#xD;
      maintain BP within 20% of preoperative baseline and BIS 40-60.&#xD;
&#xD;
      If HR &gt; 100/min and BIS 40-60 may use IV esmolol 0.5 mg/kg. If BP and/or HR &gt;20% preoperative&#xD;
      baseline, and BIS 40- 60 despite above management, may titrate IV antihypertensive agents.&#xD;
&#xD;
      For PONV prophylaxis, 30 min before end of surgery investigatorswill administer IV&#xD;
      ondansetron 8mg.&#xD;
&#xD;
      The time from end of surgery to extubation in OR will be documented with a free text note in&#xD;
      the EMR.&#xD;
&#xD;
      After extubation all patients will be transported to PACU on 2-liter Oxygen by nasal cannula,&#xD;
      which will be weaned off in the PACU.&#xD;
&#xD;
      The postoperative analgesics during Phase I of recovery in PACU will consist of IV&#xD;
      Hydromorphone 0.2-0.4 mg prn pain to maintain adequate pain control (NPRS&lt;4). During Phase II&#xD;
      of recovery patients will receive PO Hydromorphone 2mg tablets every 4-6 hours as needed for&#xD;
      pain (NPRS â‰¥ 4) and acetaminophen: 650mg PO every 6 hours&#xD;
&#xD;
      The following data will be collected every hour during phase I and phase II recovery:&#xD;
&#xD;
        -  pain (NPRS)&#xD;
&#xD;
        -  sedation (Ramsey sedation scale)&#xD;
&#xD;
        -  dizziness (1- mild, 2- moderate, 3- severe)&#xD;
&#xD;
        -  headache YES/No If yes: NPRS score HA&#xD;
&#xD;
        -  respiratory depression (hypoventilation/ apnea: RR &lt; 10 bpm., desaturation: (SpO2 &lt; 90%)&#xD;
&#xD;
        -  Sedated but still in pain (Yes/No)&#xD;
&#xD;
        -  PONV YES/NO&#xD;
&#xD;
        -  PONV receiving antiemetic treatment&#xD;
&#xD;
        -  time to first opioid administration (IV hydromorphone)&#xD;
&#xD;
        -  total amount of IV hydromorphone in PACU Phase I&#xD;
&#xD;
        -  total amount of oral analgesic (hydromorphone) in PACU Phase II&#xD;
&#xD;
        -  time to meet discharge criteria from PACU Phase I&#xD;
&#xD;
        -  time to meet discharge criteria from Phase II&#xD;
&#xD;
      Study research personnel will contact participants by phone or in the hospital at 24 hours&#xD;
      and 48 hours postoperative and at approximately one week in the Urology clinic. The study&#xD;
      research personnel will ask questions regarding pain (NPRS) and analgesic consumption. The&#xD;
      IPSS and QOR-40 questionnaires will be administered and data will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind, Randomized, Placebo Controlled Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded by using placebo or active drug supplied by Investigational Drug Pharmacy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>48 hours opioid consumption</measure>
    <time_frame>48 hours</time_frame>
    <description>Amount of opioid use in mg 48 hours after surgical procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hours opioid consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Amount of opioid use in mg 24 hours opioid consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 &amp; 48 hour Pain Burden</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>Pain scores using an 11 point numeric pain rating scale 0=no pain 10 = severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study drug side effects</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>Gabapentin related side effects as identified at 24, 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS scores</measure>
    <time_frame>24 hours, 48 hours and 1 week</time_frame>
    <description>Evaluate urinary symptoms using the International Prostate Symptom Score (IPSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOR 40 scores</measure>
    <time_frame>24 hours, 48 hours and 1 week</time_frame>
    <description>Evaluate quality of recovery using the Quality of Recovery 40 (QoR 40) questionnaire a 40 question survey scored from 40 low to 200 high (good recovery)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Anesthesia</condition>
  <condition>Urethral Obstruction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill administered 1 hour before planned surgical procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill administered orally 1 hour before planned surgical procedure</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years to 75 years&#xD;
&#xD;
          -  Patients with obstructive kidney stones undergoing elective ureteroscopy or cystoscopy&#xD;
             with Ureteral stent placement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 or more than 75 years&#xD;
&#xD;
          -  Acetaminophen allergy&#xD;
&#xD;
          -  Gabapentin allergy&#xD;
&#xD;
          -  Hydromorphone allergy&#xD;
&#xD;
          -  Chronic use of gabapentin&#xD;
&#xD;
          -  History of chronic pain (Pain for &gt; than 3 months)&#xD;
&#xD;
          -  Chronic renal insufficiency (Creatinine &gt; 1.3)&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  Psychiatric disorders (medically treated)&#xD;
&#xD;
          -  Chronic use of anticonvulsants, antidepressants, antipsychotics (use &gt; 3 months)&#xD;
&#xD;
          -  Antacids ingested within 2 hours prior to surgery&#xD;
&#xD;
          -  History of gastric or duodenal ulcer&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Inability to communicate in English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luminita Tureanu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luminita Tureanu, M.D.</last_name>
    <phone>312-695-0061</phone>
    <email>l-tureanu@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luminita Tureanu, M.D.</last_name>
      <phone>312-695-0061</phone>
      <email>l-tureanu@northwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol. 2003 Mar;169(3):1065-9; discussion 1069.</citation>
    <PMID>12576847</PMID>
  </reference>
  <reference>
    <citation>Koprowski C, Kim C, Modi PK, Elsamra SE. Ureteral Stent-Associated Pain: A Review. J Endourol. 2016 Jul;30(7):744-53. doi: 10.1089/end.2016.0129. Epub 2016 May 23. Review.</citation>
    <PMID>27125392</PMID>
  </reference>
  <reference>
    <citation>Schmidt PC, Ruchelli G, Mackey SC, Carroll IR. Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology. 2013 Nov;119(5):1215-21. doi: 10.1097/ALN.0b013e3182a9a896. Review.</citation>
    <PMID>24051389</PMID>
  </reference>
  <reference>
    <citation>Mason CJ. High frequency jet ventilation through a Robertshaw double lumen tube. Anaesthesia. 1986 Mar;41(3):330.</citation>
    <PMID>3963344</PMID>
  </reference>
  <reference>
    <citation>Bala I, Bharti N, Chaubey VK, Mandal AK. Efficacy of gabapentin for prevention of postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor. Urology. 2012 Apr;79(4):853-7. doi: 10.1016/j.urology.2011.11.050. Epub 2012 Feb 4.</citation>
    <PMID>22309784</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Luminita M. Tureanu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urethral Obstruction</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

